BIO (Biotechnology Industry Organization) and OneMedPlace share many of the same goals. Both groups want to see innovative and effective life science therapies come to the marketplace.
OneMedPlace has announced that Christine Jacobs, Co-Chair to the SEC Advisory Board on Small and Emerging companies, will discuss efforts by the SEC to address the challenges faced by small public companies.
BiognoSYS, a Swiss leader and founder of proteomics in the Greater Zurich Area, is developing targeted proteomics based on a novel mass spectrometric technology.
The Securities and Exchange Commission missed a deadline of July 4, 2012 to adopt rules lifting a general advertising ban for private securities offerings as a part of the JOBs Act.
Delenex Therapeutics, a Swiss biotech in the Greater Zurich Area is developing antibodies to treat serious medical conditions with high unmet need.
As an anchor sponsor for OneMedForum NY 2012, The Greater Zurich Area AG will be hosting a workshop Thursday morning on “Entering Europe.”
The networking reception at this historic venue will feature a special keynote in the board room of the Stock Exchange from David Weild IV, former NASDAQ Vice Chair.
Marco Estermann, Head Issuer Relations of SIX Swiss Exchange in the Greater Zurich Area sat down with OneMedRadio to discuss the growth of the Swiss biotech sector and particularly different strategies this sector employs to raise capital.
Below, we list the top ten healthcare journalists on Twitter improving the quality, accuracy and visibility of health care reporting and writing.
Napodano, a senior biotech analyst for Zacks Investment Research discusses 4 regenerative medicine companies making headway in the space.
Copyright © 2025 | WordPress Theme by MH Themes